PAKISTAN
In a major development in the regional pharmaceutical sector, Highnoon Laboratories Limited has announced a strategic partnership with Beximco Pharmaceuticals Limited, a leading Bangladeshi pharmaceutical company known for its advanced manufacturing capabilities and global regulatory accreditations.
According to an official disclosure submitted to the Pakistan Stock Exchange (PSX), the partnership is aimed at the distribution and marketing of specialized pharmaceutical products in Pakistan. These products will target high-burden therapeutic areas such as respiratory, diabetes, and cardiovascular diseases.
The companies have signed a Memorandum of Understanding (MoU) under which new therapies, dosage forms, and patient-friendly delivery systems will be introduced in Pakistan, improving both treatment outcomes and patient access to innovative medicines.
Beximco Pharmaceuticals is recognized by regulatory bodies from the USA, Australia, the European Union, Canada, and Brazil, underscoring the high-quality standards expected in this collaboration.
Highnoon Laboratories stated that this partnership not only strengthens its local portfolio but will also support the broader goal of enhancing trade relations and economic cooperation between Pakistan and Bangladesh. – ER News Desk
